Wednesday, 28 June 2017

2017 Orphan Drugs Market Growth, Trends up to 2021: Orbis Research

Latest Report Available at Orbis research Orphan Drugs Market provides pin-point analysis for changing competitive dynamics and a forward looking perspective on different factors driving or restraining industry growth.

An orphan disease refers to any rare disease which affects a smaller portion of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Request sample copy of this report at Orphan Drugs Market Research Report

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.
Orphan drug market is likely to witness a growth in future with the increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The U.S. and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan designations. Asia is likely to experience further growth with increasing drug approvals in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends of this market include progressing drug pipeline, rising treatment options in oncology and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.
The report “Global Orphan Drugs Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S, Europe and Asia along with the global market. The report profiles key players of the market including Roche, Novartis, Bristol-Myers Squibb and Celgene.


Some points from TOC:

1. Overview
1.1 Orphan Disease

1.2 Orphan Drugs

2. Global Orphan Drugs Market
2.1 Orphan Drugs Market Value
2.2 Orphan Drugs Market Forecast by Value
2.3 Orphan Drugs Market by Product
2.4 Orphan Drugs Share in Prescription Drugs Market
2.5 Orphan Drugs Share Forecast in Prescription Drugs Market

Purchase a copy of Orphan Drugs Market visit @ http://www.orbisresearch.com/contact/purchase/333707   For more information contact sales@orbisresearch.com    .

3. Regional Markets
3.1 The Americas
3.1.1 The U.S Orphan Drugs Spending Forecast
3.1.2 The U.S. Orphan Drug Volume
3.1.3 The U.S. Orphan Drug Average & Median Cost per Patient
3.1.4 The U.S. Orphan Drug Average & Median Cost per Patient Forecast
3.1.5 Canada Orphan Drugs Spending
3.1.6 Canada Orphan Drugs Spending Forecast
3.2 Europe
3.2.1 Europe Orphan Drugs Market Forecast by Value
3.2.2 Europe Orphan Drugs Market by Product
3.2.3 Europe Orphan Drug Volume
3.3 Asia
3.3.1 Japan Orphan Drug Volume
3.3.2 India Orphan Drugs Market Value Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Attractive Orphan Drug Policies
4.1.4 Rising Healthcare Expenditure
4.1.5 Improving Economic Condition
4.1.6 Increasing Prevalence of Chronic Diseases
4.2 Key Trends
4.2.1 Progressing Drug Pipeline
4.2.2 Increasing Treatment Options in Oncology
4.2.3 Increasing Scope of Gene Therapy
4.3 Challenges
4.3.1 High Cost Drugs
4.3.2 Lack of Diagnostic Systems and Trained Professionals
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry

 For any enquires before buying, connect with us @ enquiry@orbisresearch.com

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow us on Twitter: https://twitter.com/orbisresearch

No comments:

Post a Comment